A PYMNTS Company

AstraZeneca $39B Alexion Buy Hits UK Antitrust Roadblock

 |  May 25, 2021

On Tuesday, the UK’s Competition and Markets Authority (CMA) announced that it has launched an anti-competition investigation into the AstraZeneca-Alexion deal.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The agency wonders whether the transaction would hurt competition “within any market or markets in the United Kingdom,” it stated in a notice. 

    The CMA is now soliciting public comments until June 3 to help with its evaluation and aims to reach a decision by July 21. If, at that time, the agency finds any reason to believe a “realistic prospect” of threats to competition, it may launch a more in-depth, phase 2 assessment that may last up to 24 weeks or even 32 weeks in special circumstances, according to the CMA rules.

    For months, industry watchers have been watching for increased deal-making scrutiny from the US Federal Trade Commission (FTC). In March, the US antitrust authority launched a review of its current product-by-product approach to evaluating biopharma M&A. The FTC, now led by Democrats after last year’s election, stated a rise in mega deals such as those between Bristol Myers Squibb and Celgene could be contributing to high drug prices and anti-competitive behaviors such as pay-for-delay settlements.

    However, the FTC last month blessed the Alexion takeover without raising any issues. Still, the FTC’s initiative includes a collaboration with competition authorities in other countries.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.